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F R O M T H E F A M I L Y P R A C T I C E I N Q U I R I E S N E T W O R K
Clinical  Inquiries
Does microalbuminuria 
screening in diabetes
prevent complications?
■ EVIDENCE-BASED ANSWER
Screening diabetic patients for microalbumin-uria  identifies those who may benefit from
treatments that delay progression to renal failure
(strength of recommendation: B, based on extra-
polation from Level 1 treatment studies of
patients with microalbuminuria). 
No research has determined the best method
for screening for microalbuminuria, or whether
screening  in primary care populations will pro-
duce better long-term outcomes. No studies have
examined the role of microalbuminuria screening
after angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor blockers
(ARBs) have been instituted for other indications. 
■ EVIDENCE SUMMARY
Patients with diabetes mellitus have a 20% to
40% lifetime risk for development of nephropathy,
and microalbuminuria is the earliest easily
detectable marker of renal damage.1 Improved
control of blood sugar2,3 and blood pressure4
decreases but does not completely prevent devel-
opment of microalbuminuria and progression to
overt kidney failure. ACE inhibitors and ARBs
have been shown to diminish this progression
even in the absence of hypertension (the latter in
type 2 diabetes only) (Table).
No prospective randomized trials of screening
have been reported. There is uncertainty about
what method of screening is most effective and
practical in primary care settings.10 Expert opinion
recommends diagnosing microalbuminuria after 
2 positive test results,1 but whether repeated 
tests improve diagnostic accuracy is still 
controversial.10
A large randomized controlled trial showing
better long-term renal and vascular disease out-
comes would be needed to give screening for
microalbuminuria a strength of recommendation
of A. Recruiting patients for such a study, and
interpreting its results, would be difficult: many
subjects would have other indications, such as
hypertension or congestive heart failure, warrant-
ing use of potentially renoprotective medications.
■ RECOMMENDATIONS FROM OTHERS
The American Diabetes Association recommends
annual screening for microalbuminuria—after 5
years of established type 1 disease, and at time of
diagnosis for type 2 diabetes without macroalbumin-
uria. Initial screening can use 1 of 3 methods:
measurement of the albumin-to-creatinine ratio in a
random, spot collection; 24-hour collection with cre-
atinine, allowing the simultaneous measurement of
creatinine clearance; timed (eg, 4-hour or overnight)
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collection. At least 2 of 3 tests measured within a 
6-month period should show elevated levels before a
patient is said to have microalbuminuria.1
Wayne A. Hale, MD, MS, Moses Cone Health System
Family Practice Residency, Greensboro, NC; 
Joan Nashelsky, MLS, Family Practice Inquiries
Network, East Lansing, Mich
■ CLINICAL COMMENTARY
Blood pressure control and ACE inhibition
improve mortality and morbidity for patients
with diabetes mellitus type 2. Therefore, max-
imize ACE inhibitor or ARB doses, as tolerat-
ed, and aim for a blood pressure of
110–120/70–80 mm Hg (130/85 mm Hg is the
maximum).
Using this plan, I do not routinely screen for
microalbuminuria—which is, at best, a surro-
gate marker for nephropathy and poor blood
pressure control—unless I believe it 
will work as an educational and motivational
tool for patients who are less committed to
self-care. 
If serum creatinine becomes elevated, a 24-
hour urine collection to examine volume, creati-
nine clearance, and protein can be used to help
develop a negotiated care plan with the patient,
which may or may not include referral. Until
there is different evidence about screening and
treatment options for microalbuminuria, 
I see no need to screen when the above plan is 
in effect.
Stephen A. Wilson, MD, University of Pittsburgh
Medical Center, St. Margaret Family Practice Residency,
Pittsburgh, Pa
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DM type Medication NNT Time (years) To prevent endpoint
1 ACE inhibitor 7.9* 2 Clinical proteinuria5
(Captopril)
2 ACE inhibitor 6.3* 5 Macroalbuminuria6
(Enalapril)
2 ACE inhibitor 2.4* 7 Significant proteinuria7
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*Normotensive subjects
†Myocardial infarction, revascularization procedure, stroke, cardiovascular death, congestive heart failure requiring hospitalization, overt
nephropathy, renal dialysis, or laser treatment for retinopathy
DM, diabetes mellitus; NNT, number needed to treat; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker
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Is MRI useful for evaluation
of acute low back pain?
■ EVIDENCE-BASED ANSWER
Magnetic resonance imaging (MRI) is rarelyhelpful in the evaluation of acute low back
pain. Limited evidence suggests that MRI may be
useful in further assessing “red flags” in the 
history or physical exam.
MRI has a high sensitivity and specificity in the
detection of cancer or infection, but it is not partic-
ularly specific when evaluating lumbar radiculopa-
thy. Poor specificity can lead to finding clinically
irrelevant abnormalities.1 The overall evidence for
the appropriate use of MRI in low back pain is lim-
ited and weak2,3 (strength of recommendation: C,
based on limited randomized controlled trials).
■ EVIDENCE SUMMARY
Radiologic imaging of any kind is seldom needed in
the evaluation of acute low back pain unless there
are “red flags” suggestive of cancer, infection, or
fracture (Table). Conduct a thorough history and
review of systems to risk-stratify patients that may
benefit from imaging. 
One study of patients with low back pain identi-
fied risk factors for cancer, including age >50
years, prior cancer, unexplained weight loss, pain
lasting >1 month, and no relief with bed rest.4 An
elevated erythrocyte sedimentation rate of >50
mm/hr in the setting of these risk factors should
prompt the clinician to order an MRI or bone scan.5
An analysis of systematic reviews and original
articles by Jarvik and Deyo reported sensitivities for
MRI (83% to 93%) and for radionucleotide scan-
ning (74% to 98%) in detecting cancer.6 MRI
exhibits the best sensitivity (96%) and specificity
Red flags for underlying 
causes of low back pain
Condition Red flags
Cancer Age >50
History of cancer
Unexplained weight loss
Failure to improve after 
4 to 6 weeks of 
conservative 
low back pain therapy
Spinal infection Fever >38°C
History of intravenous 
drug abuse
Urinary tract infection
Neurologic Cauda equina symptoms
emergencies or Progressive neurologic deficit
urgencies Suspicion of ankylosing 
spondylitis
Unrelenting night pain 
or pain at rest
Pain with distal numbness 
or leg weakness
Fracture History of osteoporosis
Chronic oral steroid use
Serious accident or injury
Adapted from Institute for Clinical Systems Improvement10
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